Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Original Article

Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis

Moon Haeng Hur, Yuri Cho, Do Young Kim, Jae Seung Lee, Gyoung Min Kim, Hyo-Cheol Kim, Dong Hyun Sinn, Dongho Hyun, Han Ah Lee, Yeon Seok Seo, In Joon Lee, Joong-Won Park, Yoon Jun Kim

Clin Mol Hepatol. 2023;29(3):763-778. Published online May 30, 2023

DOI: https://doi.org/10.3350/cmh.2023.0076

View: 2736 Download: 178 Crossref: 2

Editorial

Optimal sequence of systemic therapy after sorafenib failure in patients with hepatocellular carcinoma

Sojung Han, Do Young Kim

Clin Mol Hepatol. 2020;26(3):305-308. Published online July 1, 2020

DOI: https://doi.org/10.3350/cmh.2020.0096

View: 4163 Download: 108 Web of Science: 5 Crossref: 5

Review

Switching to systemic therapy after locoregional treatment failure: Definition and best timing

Sadahisa Ogasawara, Yoshihiko Ooka, Keisuke Koroki, Susumu Maruta, Hiroaki Kanzaki, Kengo Kanayama, Kazufumi Kobayashi, Soichiro Kiyono, Masato Nakamura, Naoya Kanogawa, Tomoko Saito, Takayuki Kondo, Eiichiro Suzuki, Shingo Nakamoto, Akinobu Tawada, Tetsuhiro Chiba, Makoto Arai, Jun Kato, Naoya Kato

Clin Mol Hepatol. 2020;26(2):155-162. Published online January 15, 2020

DOI: https://doi.org/10.3350/cmh.2019.0021n

View: 9722 Download: 408 Web of Science: 41 Crossref: 38

Original Article

Vimentin as a potential therapeutic target in sorafenib resistant HepG2, a HCC model cell line

Ankita Makol, Harpreet Kaur, Sakshi Sharma, Shruthi Kanthaje, Ramanpreet Kaur, Anuradha Chakraborti

Clin Mol Hepatol. 2020;26(1):45-53. Published online September 30, 2019

DOI: https://doi.org/10.3350/cmh.2019.0031

View: 7616 Download: 250 Web of Science: 17 Crossref: 14

Case Report

Complete response of advanced hepatocellular carcinoma to sorafenib : another case and a comprehensive review

Tae Suk Kim, Ji Hoon Kim, Baek hui Kim, Young-Sun Lee, Yang Jae Yoo, Seong Hee Kang, Sang-June Suh, Young Kul Jung, Yeon Seok Seo, Hyung Joon Yim, Jong Eun Yeon, Kwan Soo Byun

Clin Mol Hepatol. 2017;23(4):340-346. Published online June 20, 2017

DOI: https://doi.org/10.3350/cmh.2016.0070

View: 16054 Download: 198 Web of Science: 18 Crossref: 18

Original Article

A comparative study of sorafenib and metronomic chemotherapy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma with poor liver function

Hyun Yang, Hyun Young Woo, Soon Kyu Lee, Ji Won Han, Bohyun Jang, Hee Chul Nam, Hae Lim Lee, Sung Won Lee, Do Seon Song, Myeong Jun Song, Jung Suk Oh, Ho Jong Chun, Jeong Won Jang, Angelo Lozada, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon

Clin Mol Hepatol. 2017;23(2):128-137. Published online May 10, 2017

DOI: https://doi.org/10.3350/cmh.2016.0071

View: 11435 Download: 190 Web of Science: 24 Crossref: 21

Editorial

Can metronomic chemotherapy be an alternative to sorafenib in advanced hepatocellular carcinoma?

Do Young Kim

Clin Mol Hepatol. 2017;23(2):123-124. Published online June 23, 2017

DOI: https://doi.org/10.3350/cmh.2017.0107

View: 6767 Download: 118

Original Article

Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis

Jung Min Lee, Byoung Kuk Jang, Yoo Jin Lee, Wang Yong Choi, Sei Myong Choi, Woo Jin Chung, Jae Seok Hwang, Koo Jeong Kang, Young Hwan Kim, Anil Kumar Chauhan, Soo Young Park, Won Young Tak, Young Oh Kweon, Byung Seok Kim, Chang Hyeong Lee

Clin Mol Hepatol. 2016;22(1):160-167. Published online March 28, 2016

DOI: https://doi.org/10.3350/cmh.2016.22.1.160

View: 11178 Download: 196 Web of Science: 79 Crossref: 69

Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy

Jung Gil Park

Clin Mol Hepatol. 2015;21(3):287-294. Published online September 30, 2015

DOI: https://doi.org/10.3350/cmh.2015.21.3.287

View: 8397 Download: 73 Web of Science: 26 Crossref: 28

Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells

Ha Ra Gu, Su Cheol Park, Su Jin Choi, Jae Cheol Lee, You Cheoul Kim, Chul Ju Han, Jin Kim, Ki Young Yang, Yeon Joo Kim, Geum Youb Noh, So Hyeon No, Jae-Hoon Jeong

Clin Mol Hepatol. 2015;21(1):49-59. Published online March 25, 2015

DOI: https://doi.org/10.3350/cmh.2015.21.1.49

View: 11684 Download: 121 Web of Science: 29 Crossref: 28

Liver Imaging

Magnetic resonance imaging following treatment of advanced hepatocellular carcinoma with sorafenib

Joon-Il Choi, David K Imagawa, Priya Bhosale, Puneet Bhargava, Temel Tirkes, Tara E Seery, Chandana Lall

Clin Mol Hepatol. 2014;20(2):218-222. Published online June 30, 2014

DOI: https://doi.org/10.3350/cmh.2014.20.2.218

View: 6418 Download: 78 Web of Science: 11 Crossref: 12

The Korean Journal of Hepatology Elsewhere

The effect of sorafenib on hepatic stellate cells: implication of its effect on tumor microenvironment

Jung Il Lee

Clin Mol Hepatol. 2010;16(4):418-419. Published online December 31, 2010

DOI: https://doi.org/10.3350/kjhep.2010.16.4.418

View: 4519 Download: 45 Crossref: 1

2

Molecular targeting for treatment of advanced hepatocellular carcinoma

Il Han Song

Clin Mol Hepatol. 2009;15(3):299-308. Published online September 30, 2009

DOI: https://doi.org/10.3350/kjhep.2009.15.3.299

View: 5434 Download: 36 Crossref: 6

7

The Korean Journal of Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma

Jeong Heo

Clin Mol Hepatol. 2009;15(2):227-230. Published online June 30, 2009

DOI: https://doi.org/10.3350/kjhep.2009.15.2.227

View: 3885 Download: 26 Crossref: 1

The Korean Journal of The Efficacy of Sorafenib for Patients With Advanced Hepatocellular Carcinoma

Jeong Heo

Clin Mol Hepatol. 2007;13(4):576-580. Published online December 20, 2007

DOI: https://doi.org/10.3350/kjhep.2007.13.4.576

View: 3132 Download: 15

Original Article

Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after Atezolizumab/Bevacizumab Failure: A real-world study

Young Eun Chon, Dong Yun Kim, Mina Kim, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Yeonjung Ha, Joo Ho Lee, Kwan Sik Lee, Beodeul Kang, Jung Sun Kim, Hong Jae Chon, Do Young Kim

Received December 21, 2023 Accepted March 8, 2024

DOI: https://doi.org/10.3350/cmh.2023.0553 [Accepted]

View: 630 Download: 119

1 |

Viewed By 5338	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 5288	MAFLD: How is it different from NAFLD?
Viewed By 5178	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 3880	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 3832	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 114	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 103	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 76	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 65	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach
Cited By 52	MAFLD: How is it different from NAFLD?

Search